Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Escalation Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Pediatric Patients With Refractory or Relapsed Acute Leukemias.

NCT00315705 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00315705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00315705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Escalation Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Pediatric Patients With Refractory or Relapsed Acute Leukemias.
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2006
Completion date
May 31, 2010
Enrollment
50 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myelogenous leukemia, relapsed leukemia